From Variant to Therapy: How CKB Powers Precision Oncology

Behind the Curtain: How the CKB Maintains Its Database of Clinical Variants

CKB and Northwestern Medicine Webinar – Recap & Audience Pulse

This panel was designed with purpose – to align with major commercial epilepsy panels, while going deeper on what truly matters: clinically actionable evidence.

In a field where speed, accuracy, and confidence are critical, our goal is simple: empower clinicians, researchers, and testing laboratories with better genomic intelligence to improve outcomes for people living with epilepsy.

Each quarter, we rotate a focused set of genes in Mastermind CORE – selected for diagnostic relevance and aligned with awareness initiatives. This quarter’s update features 10 newly added genes spanning sensory loss, neurodevelopmental, autoinflammatory, cardiopulmonary, and connective-tissue disorders – each linked to early-onset or multisystemic disease where rapid, accurate interpretation can change care trajectories. 

The Q4 set is available through December 31, 2025, alongside our 23 permanently accessible Mastermind CORE genes, ensuring continuity for clinicians and researchers while keeping content timely and impact-driven.

Raising Awareness for Muscular Dystrophy: Why Visibility Changes Outcomes

The Future of Newborn Screening: Why It Matters More Than Ever

A Legacy of Love: Honoring Willow and the Fight Against MSD

Meet our team and discover how we’re enabling clinical teams to interpret more variants in less time – without sacrificing accuracy.

Join us at AMP to see how literature-based RWE goes beyond traditional RWD – extracting patient- and variant-level insights from thousands of papers to power better trial design, label expansion, and disease understanding. We’ll share oncology case studies and show how clinicians use CKB’s expertly curated evidence to refine stratification and guide more precise therapy and trial selection.
 

AMP Corporate Workshop | Nov 12 | 10:00-10:50am, Room 156AB, Level 1
Revealing the Value of Literature-Based Real-World Evidence: Transforming Trial Design, Label Expansion, and Clinical Decision-Making
Speakers: Mark Kiel, MD, PhD & Cara Statz, PhD

At this year’s AI Drug Discovery & Development Summit, Genomenon CSO, Mark Kiel, MD, PhD, will join a panel discussion exploring how knowledge graphs unify genetic, proteomic, and clinical data into AI-ready models that accelerate target discovery and deepen biological understanding. Dr. Kiel will be joined by leading experts from across the drug discovery ecosystem in a dynamic conversation on the future of data-driven discovery, a session you won’t want to miss.
 

Genomenon Panel Discussion | Nov 20 | 2:30pm-3:30pm
Normalizing Complex Datasets: Ensuring AI-Ready Data for Biological Research
Speaker: Mark Kiel, MD, PhD

NEWS & ANNOUNCEMENTS

We recently presented a joint webcast featuring Dr. Nathan Fortier, Director of Research, Dr. Rana Smalling (Field Application Scientist), members of the Golden Helix team, and Denice Belandres (Senior Manager of Customer Success) from the Genomenon team. This webcast demonstrated how VarSeq integrates Genomenon Mastermind and Genomenon Cancer Knowledgebase (CKB), enhancing germline and somatic variant analysis and clinical reporting.

Need variant clarity? Let’s talk. Whether you’re focused on rare disease, oncology, or clinical interpretation at scale, Genomenon’s team is ready to help.